Unicycive Therapeutics, Inc.
NASDAQ:UNCYBiotechnology
-$0.24 today
- Market cap
- $104.19M
- Beta
- 1.73
- P/E (TTM)
- -40.8
- EPS (TTM)
- -$0.17
Volume 1.39M
Average 0.65M
UNCY Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Unicycive Therapeutics, Inc.NASDAQ: UNCY
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$140.65M, compared with -$100.7M a year earlier.
Context
- Retained earnings amounted to 218.4% of total assets at the end of Q1 FY2026, down 141.9 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -39.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (127.83M) USD
- Year-over-year change
- -26.2%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (127.83M) | -26.2% |
| FY2024 | 2024-12-31 | (101.27M) | -56.9% |
| FY2023 | 2023-12-31 | (64.54M) | -89.8% |
| FY2022 | 2022-12-31 | (34M) | -113.3% |
| FY2021 | 2021-12-31 | (15.94M) | — |
Retained Earnings vs competitors
How UNCY compares with its peers on the latest reported figures
- Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -39.7% is the lowest of 10, against a peer median of -13.0%.
- Retained earnings amounts to 218.4% of total assets for UNCY, versus a peer median of 304.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
HYFTMindWalk Holdings Corp. | Jan 2026 | -CA$139.95M CAD | -10.5% | — | 604.1% |
| Mar 2026 | -$140.65M USD | -39.7% | — | 218.4% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | -$293.92M USD | -35.7% | — | 272.6% |
| Mar 2026 | -$310.49M USD | -38.5% | — | 294.4% | |
| Mar 2026 | -$455.02M USD | +7.5% | — | 252.7% | |
| Mar 2026 | -$461.46M USD | -10.8% | — | 994.9% | |
| Mar 2026 | -$464.49M USD | -20.3% | — | 481.0% | |
| Mar 2026 | -$641.16M USD | -19.4% | — | 337.9% | |
| Mar 2026 | -$717.32M USD | -8.9% | — | 304.8% | |
CBUSCibus, Inc. | Mar 2026 | -$879.47M USD | -13.0% | — | 271.3% |
| Peer median (excluding UNCY) | — | -13.0% | — | 304.8% | |
Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
Intrinsic Alpha fair value
Locked
Current Price
$3.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.